Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Adverse drug reaction monitoring in a secondary care hospital in South India

Open access
Arulmani, R., Rajendran, S.D., Suresh, B. · 2008 · British Journal of Clinical Pharmacology

Abstract

What is already known about this subject • The benefits of adverse drug reaction (ADR) monitoring are well‐known. • Poor awareness and nonavailability of a central co‐ordinating body resulted in lack of ADR monitoring in India. • The National Pharmacovigilance Programme was recently initiated, encouraging ADR monitoring in selected centres, including our centre. What this study adds • This is the first study of its kind at GHQH, Ootacamund that has provided insight into the burden of ADRs here. • The incidence and severity of ADRs documented in our study is lower than those reported in comparable populations in Western studies but more than those reported in India. Aims: To ascertain the current burden of ADRs at a Government hospital in Ooty and to assess the severity of reported ADRs and the additional financial burden associated with ADRs. Methods: A prospective, spontaneous reporting study was conducted over a period of 9 months of inpatient admissions to the medical wards, co‐ordinated by clinical pharmacists. The WHO definition of an ADR was adopted. The Naranjo algorithm scale was used for causality assessment. Confirmed ADRs were classified according to the Wills & Brown [7] method and assessed for severity and patient outcomes. The average cost incurred in treating the ADRs was calculated. Results: Of the total of 187 adverse drug events (ADEs) reported, 164 reports from 121 patients were confirmed as ADRs, giving an overall incidence of 9.8%. This included 58 (3.4%) ADR related admissions and 63 (3.7%) ADRs occurring during the hospital stay. About two thirds of the reactions (102, 62.2%) were classified as probable. The majority of the reactions (88, 53.7%) were mild. Most patients (119, 72.6%) recovered from the incidence. The majority of the reactions were of type H (100, 61%) which indicates that they were not predictable and not potentially preventable. An average cost of 481 rupees (£6) was spent on each patient to manage ADRs. Conclusions: The incidence and severity of ADRs documented in our study are lower than those reported in comparable populations in Western studies but more than those reported in India.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.2007.02993.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 193

Metadata

Authors
Arulmani, R., Rajendran, S. D., & Suresh, B.
Venue
British Journal of Clinical Pharmacology
Publisher
Wiley
Published
2007-08-15
Volume
65
Issue
2
Pages
210-216
ISSN
  • 0306-5251 (ISSN-L)
  • 1365-2125
OpenAlex
W2040619589
Cited by
193
References
1
FWCI
4.58
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse drug reaction monitoring in a secondary care hospital in South India. https://app.cochat.ai/papers/10.1111/j.1365-2125.2007.02993.x
The paper
Arulmani, R., Rajendran, S. D., & Suresh, B. (2008). Adverse drug reaction monitoring in a secondary care hospital in South India. British Journal of Clinical Pharmacology. https://doi.org/10.1111/j.1365-2125.2007.02993.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.